From Inside the Games
Colombian wheelchair racer Francisco Sanclemente is now eligible to compete after serving his 13-month suspension.
The International Paralympic Committee (IPC) confirmed the marathon racer had committed an “unintentional” violation of anti-doping rules at the 2019 Berlin Marathon.
According to the IPC, Sanclemente returned “an adverse analytical finding for a prohibited substance” in a urine sample provided during an in-competition test on September 29 2019 after finishing the race.
The sample was found to contain metabolites of sibutramine. which is included on the World Anti-Doping Agency’s prohibited list under the class S6b.
The IPC accepted Sanclemente neither consumed sibutramine in competition nor in order to enhance his sporting performance.
“Following analysis of the evidence presented by the athlete and the WADA-accredited laboratories in Dresden and Utah, the IPC was satisfied that the ADRV (anti-doping rule violation) was unintentional, without significant fault or negligence on the part of the athlete, and that the source of the prohibited substance was the athlete’s prior out-of-competition consumption of a contaminated weight-loss supplement which did not list sibutramine among its ingredients,” a statement from the IPC read.
“Each athlete is strictly liable for the substances found in his or her sample.
“An anti-doping rule violation occurs whenever a prohibited substance (or its metabolites or markers) is found in his or her bodily specimen, whether or not the athlete intentionally or unintentionally used a prohibited substance or was negligent or otherwise at fault.”